A Prospective Single-center Study on CNI-free GVHD Prophylaxis with Everolimus Plus Mycophenolate Mofetil in Allogeneic HCT

Overview

Journal Ann Hematol

Specialty Hematology

Date 2021 Mar 23

PMID 33755792

Citations 1

Authors

Henning Schafer

Jacqueline Blumel-Lehmann

Gabriele Ihorst

Hartmut Bertz

Ralph Wasch

Robert Zeiser

Jurgen Finke

Reinhard Marks

Affiliations

Soon will be listed here.

Abstract

We report a single-center phase I/II trial exploring the combination of everolimus (EVE) and mycophenolate mofetil (MMF) as calcineurin inhibitor (CNI)-free GVHD prophylaxis for 24 patients with hematologic malignancies and indication for allogeneic HCT after a high dose or reduced-intensity ablative conditioning. The study was registered as EudraCT-2007-001892-12 and Clinicaltrials.gov as NCT00856505. All patients received PBSC grafts and no graft failure occurred. 7/24 patients (29%) developed acute grades III and IV GVHD (aGVHD), 16/19 evaluable patients (84%) developed chronic GVHD (cGVHD) of all grades, and 6/19 (31.6%) of higher grades. No severe toxicities related to study medication were observed. The median follow-up of all surviving patients is 2177 days. The 3-year OS was 45.2% (95% CI: 27.4-61.4%), and the 3-year PFS was 38.7% (95% CI: 22.0-55.1%). The cumulative incidence of relapse at 1 year and 3 year was 25% (95% CI: 12.5-50.0%), and 33.3% (95% CI: 18.9-58.7%), the cumulative incidence of NRM at 1 year and 3 years was 20.8% (95%CI: 9.6-45.5%), and 29.2% (95%CI: 15.6-54.4%), respectively. The utilization of CNI-free GVHD prophylaxis with EVE+MMF resulted in high rates of acute and chronic GVHD. Therefore, we do not recommend a CNI-free combination of mTOR inhibitor EVE with MMF as the sole GVHD prophylaxis. In subsequent studies, this combination should be modified, e.g., with further components like post-transplant cyclophosphamide (PTCy) or anti-thymocyte globulin (ATG).

Citing Articles

Acute Graft-versus-Host Disease: An Update on New Treatment Options.

Patel D, Crain M, Pusic I, Schroeder M Drugs. 2023; 83(10):893-907.

PMID: 37247105 DOI: 10.1007/s40265-023-01889-2.

References

Kharfan-Dabaja M, Mhaskar R, Reljic T, Pidala J, Perkins J, Djulbegovic B . Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2014; (7):CD010280. PMC: 10945354. DOI: 10.1002/14651858.CD010280.pub2. View

Armand P, Kim H, Sainvil M, Lange P, Giardino A, Bachanova V . The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol. 2016; 173(1):96-104. PMC: 4809783. DOI: 10.1111/bjh.13931. View

San Segundo D, Ruiz J, Izquierdo M, Fernandez-Fresnedo G, Gomez-Alamillo C, Merino R . Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation. 2006; 82(4):550-7. DOI: 10.1097/01.tp.0000229473.95202.50. View

Pinana J, Valcarcel D, Fernandez-Aviles F, Martino R, Rovira M, Barba P . MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. Bone Marrow Transplant. 2010; 45(9):1449-56. DOI: 10.1038/bmt.2009.362. View

Finke J, Bethge W, Schmoor C, Ottinger H, Stelljes M, Zander A . Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009; 10(9):855-64. DOI: 10.1016/S1470-2045(09)70225-6. View

Filipovich A, Weisdorf D, Pavletic S, Socie G, Wingard J, Lee S . National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11(12):945-56. DOI: 10.1016/j.bbmt.2005.09.004. View

Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E . A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004; 34(7):621-5. DOI: 10.1038/sj.bmt.1704647. View

Grullich C, Bertz H, Spyridonidis A, Muller C, Finke J . A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation. Bone Marrow Transplant. 2008; 41(10):845-50. DOI: 10.1038/sj.bmt.1705989. View

Platzbecker U, von Bonin M, Goekkurt E, Radke J, Binder M, Kiani A . Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. Biol Blood Marrow Transplant. 2009; 15(1):101-8. DOI: 10.1016/j.bbmt.2008.11.004. View

10.

Cutler C, Li S, Ho V, Koreth J, Alyea E, Soiffer R . Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood. 2006; 109(7):3108-14. PMC: 1852220. DOI: 10.1182/blood-2006-09-046219. View

11.

Armand P, Gibson C, Cutler C, Ho V, Koreth J, Alyea E . A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012; 120(4):905-13. PMC: 3412351. DOI: 10.1182/blood-2012-03-418202. View

12.

Perkins J, Field T, Kim J, Kharfan-Dabaja M, Fernandez H, Ayala E . A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2010; 16(7):937-47. DOI: 10.1016/j.bbmt.2010.01.010. View

13.

Gooley T, Leisenring W, Crowley J, Storer B . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999; 18(6):695-706. DOI: 10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o. View

14.

Zeiser R, Leveson-Gower D, Zambricki E, Kambham N, Beilhack A, Loh J . Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood. 2007; 111(1):453-62. PMC: 2200823. DOI: 10.1182/blood-2007-06-094482. View

15.

Sandmaier B, Kornblit B, Storer B, Olesen G, Maris M, Langston A . Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Lancet Haematol. 2019; 6(8):e409-e418. PMC: 6686903. DOI: 10.1016/S2352-3026(19)30088-2. View

16.

Mielke S, Lutz M, Schmidhuber J, Kapp M, Ditz D, Ammer J . Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis. Bone Marrow Transplant. 2014; 49(11):1412-8. DOI: 10.1038/bmt.2014.170. View

17.

Tenderich G, Fuchs U, Zittermann A, Muckelbauer R, Berthold H, Koerfer R . Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. Clin Transplant. 2007; 21(4):536-43. DOI: 10.1111/j.1399-0012.2007.00686.x. View

18.

Pulsipher M, Langholz B, Wall D, Schultz K, Bunin N, Carroll W . The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood. 2014; 123(13):2017-25. PMC: 3968388. DOI: 10.1182/blood-2013-10-534297. View

19.

Al-Kadhimi Z, Gul Z, Chen W, Smith D, Abidi M, Deol A . High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients. Biol Blood Marrow Transplant. 2014; 20(7):979-85. PMC: 4110977. DOI: 10.1016/j.bbmt.2014.03.016. View

20.

Ruutu T, de Wreede L, van Biezen A, Brand R, Mohty M, Dreger P . Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. Bone Marrow Transplant. 2015; 50(12):1542-50. DOI: 10.1038/bmt.2015.186. View